Why the study?
Ginsenoside Rg3 has antitumor activities in various carcinomas, but its targets and mechanisms of action in hepatocellular carcinoma were not fully understood.
Does ginsenoside Rg3 suppress tumor growth and angiogenesis in an orthotopic murine HCC model?
Population
TCGA-LIHC cohort and immunocompetent C57BL/6 mice with orthotopic Hepa1-6 HCC tumors
Comparison
Rg3 administration vs controls
Design
Bioinformatics analysis combined with in vitro and in vivo animal study
Key result
Ginsenoside Rg3 administration suppressed tumor growth and angiogenesis in vivo, restored Kupffer cell function, and blocked myeloid-derived suppressor cell recruitment in a murine HCC model.
Authors
Loading...
Does not support clinical use of Rg3 in HCC; leaves open its therapeutic potential pending human validation.
Does ginsenoside Rg3 suppress tumor growth and angiogenesis in an orthotopic murine HCC model?
Ginsenoside Rg3 suppresses hepatocellular carcinoma progression by modulating Kupffer cell function and reducing MDSC recruitment in a murine model.
Zhao et al. (2024) studied Hepatocellular carcinoma (HCC). Ginsenoside Rg3 was evaluated on Tumor growth and angiogenesis. Ginsenoside Rg3 administration suppressed tumor growth and angiogenesis in vivo, restored Kupffer cell function, and blocked myeloid-derived suppressor cell recruitment in a murine HCC model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: